Generation of a liver targeting fusion interferon and its bioactivity analysis in vitro

Pharmazie

Volumn 66, Issue 10, 2011, Pages 761-765

  Cai, Gangming ^a   Jiang, Mengjun ^a   Zhou, Yaoyuan ^a   Gu, Xiaobo ^a   Zhang, Bo ^a   Zou, Meifen ^a   Zhou, Xingqin ^a   Bao, Jiandong ^a   Cao, Guoxian ^a   Zhang, Rongjun ^a  

^a BEIJING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBINTERFERON ALPHA2B; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PROPIDIUM IODIDE; PROTEIN BAX; PROTEIN BCL 2; RHODAMINE B;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LETHALITY; PROTEIN EXPRESSION; SUPERNATANT; WESTERN BLOTTING;

ANTIVIRAL AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL DEATH; CELL LINE; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HUMANS; INTERFERON-ALPHA; LIVER; MICROSCOPY, FLUORESCENCE; S PHASE;

EID: 84055200287     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2011.1044     Document Type: Article

References (20)

1. Aramaki Y, Lee I, Arima H, Sakamoto T, Magami Y, Yoshimoto T, Moriyasu F, Mizuguchi J, Koyanagi Y, Nikaido T, Tsuchiya S (2003) Efficient gene transfer to hepatoblastoma cells through asialoglycoprotein receptor and expression under the control of the cyclin A promoter. Biol Pharm Bull 26: 357-360. (Pubitemid 39663624)
2. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR (2007) Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov. 6: 975-990. (Pubitemid 350201788)
3. Cai G, Jiang M, Zhang B, Zhou Y, Zhang L, Lei J, Gu X, Cao G, Jin J, Zhang R (2009) Preparation and biological evaluation of a glycosylated fusion interferon directed to hepatic receptors. Biol Pharm Bull 32: 440-443.
4. Grace Mj, Lee S, Bradshaw S, Chapman J, Spond J, Cox S, Delorenzo M, Brassard D, Wylie D, Cannon-Carlson S, Cullen C, Indelicato S, Voloch M, Bordens R (2005) Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J Biol Chem 280: 6327-6336.
5. Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2: 214-221.
6. Hudgin RL, Ashwell G (1974). Studies on the role of glycosyltransferases in the hepatic binding of asialoglycoproteins. J Biol Chem 249: 7269-7272.
7. Jones J, Shepherd J, Baxter L, Gospodarevskaya E, Hartwell D, Harris P, Price A (2009). Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. Health Technol Assess 13: 1-172, iii.
8. Lee YC, Stowell CP, Krantz MJ (1976) 2-Imino-2-methoxyethyl 1-thioglycosides: new reagents for attaching sugars to proteins. Biochemistry 15: 3956-3963.
9. Li Y, Huang G, Diakur J, Wiebe Li (2008) Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development. Curr Drug Deliv 5: 299-302.
10. Liang GL, Jin J, Hu MY, Zhang RJ, Yu YH (1998). Synthesis of sialoglycoprotein. Chin J Pharmaceut (in Chinese) 6: 248-249.
11. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C (2002) Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 303: 540-548. (Pubitemid 35231224)
12. Skehan P, Storeng R, Scudiero D, Monks A, Mcmahon J, Vistica D, Warren Jt, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112. (Pubitemid 20213250)
13. Sung C, Nardelli B, Lafleur DW, Blatter E, Corcoran M, Olsen HS, Birse CE, Pickeral OK, Zhang J, Shah D, Moody G, Gentz S, Beebe L, Moore PA (2003) An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates. J Interferon Cytokine Res 23: 25-36. (Pubitemid 36308059)
14. Sureau C, Romet-Lemonne JL, Mullins JI, Essex M (1986). Production of hepatitis B virus by a differentiated human hepatoma cell line after transfection with cloned circular HBV DNA. Cell. 47: 37-47. (Pubitemid 17181531)
15. Takamatsu S, Fukuta K, Asanagi M, Abe R, Yokomatsu T, Fujibayashi Y, Makino T (2003) Monitoring biodistribution of glycoproteins with modified sugar chains. Biochim Biophys Acta 1622: 179-191. (Pubitemid 36962956)
16. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 1: 1112-1116.
17. Voigt W (2005) Sulforhodamine B assay and chemosensitivity. Methods Mol Med 110: 39-48.
18. Hepatitis B: Fact sheets WHO., Http://Www.Who.Int/Mediacentre/Factsheets/ Fs204/En.
19. Wills RJ (1990). Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19: 390-399.
20. Zhong Y, Fu X, Guan C (1995) Preparation of galactosyl-interferon α-1 and its hepatic targeting property. Chin J Med Chem (in Chinese) 163-168.